Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Arcus Phase 2 EDGE-Gastric trial in upper GI cancers completed, 332 enrolledOct 26Trial updateArcus Biosciences, Inc.domvanalimab
Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 updateOct 19Trial updateArcus Biosciences, Inc.domvanalimab
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca